the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings ...

According to statistics from Cancer Research UK, cases of AML have increased by 12% in the UK since the 1990s. Professor Nigel Russell, Honorary Consultant at Guy's and St Thomas' NHS Foundation ...

For months, college student Breeze Hunter, 22, felt pressure and pain in her head. “I had a lot of fluid in my ears, which ...

The European Commission has approved Astellas’ Xospata (gilteritinib) for patients with relapsed or refractory FLT3-positive acute myeloid leukemia (AML), cementing its lead over a rival drug ...

DALLAS, April 22, 2025 (GLOBE NEWSWIRE) -- AML GO (Pty) Ltd (“AML GO”), a subsidiary of UPAY Inc. (OTCQB: UPYY) and a leading provider of advanced anti-money laundering (AML) and compliance ...

Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue ... With this INN now given and prior approval by the United States ...

after induction therapy (R/R AML) and is approved in all nine countries submitted in the European Union (EU). This Phase 3 "MIRACLE” trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation) ...

after induction therapy (R/R AML) and is approved in all nine countries submitted in the European Union (EU). This Phase 3 "MIRACLE" trial (derived from Moleculin R/R AML AnnAraC Clinical ...

With this INN now given and prior approval by the United States Adopted ... Phase 3 MIRACLE trial of Annamycin for the treatment R/R AML and look forward to reporting initial data in the second ...